lung cancer Archives

Oncotarget News

Rare Non-Small Cell Lung Cancer with Brain Metastases Responds to Amivantamab Monotherapy

June 11, 2025

This case challenges current paradigms, demonstrating that amivantamab monotherapy can effectively target rare EGFR mutations, achieve durable extracranial and CNS disease control, and potentially overcome blood-brain barrier limitations.”BUFFALO, NY -... read more

Oncotarget

Cigarette Smoke and DNA Repair Deficiency Drive Lung Cancer Development

June 9, 2025

In this study, we investigated the interplay between cigarette smoke, DNA damage and repair, focusing on the Nucleotide Excision Repair (NER) protein Xeroderma Pigmentosum Group C (XPC).”BUFFALO, NY - June... read more

Oncotarget

New Genetic Mutation Linked to Drug Resistance in Non-Small Cell Lung Cancer Patient

February 6, 2025

Here we present a case of a patient with stage IV CD-74-ROS1 fusion NSCLC discovered initially with RNA next generation sequencing (NGS) who acquired resistance to lorlatinib after 6 months... read more

Oncotarget

Behind the Study: DLL3, ASC1, TTF-1 & Ki-67 in Precision Medicine for SCLC

November 18, 2024

Samuel Silva from the Department of Pathology at Federal University of Ceará in Fortaleza, Brazil, discusses a research paper he co-authored that was published in Oncotarget Volume 15, titled, “Relationship... read more

Oncotarget

Precision Medicine in SCLC: DLL3, ASC1, TTF-1, and Ki-67 Expression

November 6, 2024

This study presents an observational, cross-sectional analysis of 64 patients diagnosed with small cell lung cancer (SCLC) at a reference laboratory for thoracic pathology between 2022 and 2024.”BUFFALO, NY -... read more

Oncotarget

Assessment of Serum Tumor Markers CEA, CA-125, and CA19-9 as Adjuncts in Non-small Cell Lung Cancer Management

June 19, 2024

these inexpensive, widely available tests with rapid turnaround times and relatively short half-lives (CEA, CA-125, and CA19-9) are perfectly situated to serve as adjunctive clinical tools in the management of... read more

Figure 2: Preemptive combinations. (A) EGFR-Mutant-Driven NSCLC. See text. (B) METex14-Driven NSCLC. See text.

Oncotarget

“From Osimertinib to Preemptive Combinations” by Dr. Blagosklonny

March 19, 2024

Here I will re-introduce the notion of preemptive combinations (PC) of targeted drugs.”BUFFALO, NY- March 19, 2024 – A new research perspective was published by Mikhail V. Blagosklonny M.D.,... read more

Figure 2: Immunoblot assessment of effects on cell-cycle, pro- and anti-apoptosis signaling events mediated by Sacituzumab govitecan plus platinum-based chemotherapeutics in human TNBC, SCLC, and UBC tumor-lines.

Oncotarget

Sacituzumab Govitecan Plus Platinum-based Chemotherapy in Breast, Bladder, and Lung Carcinomas

March 4, 2024

these results support the rationale and potential for favorable clinical outcomes of combining SG therapy with platinum-based chemotherapeutics in solid tumors.”BUFFALO, NY- March 4, 2024 – A new research paper... read more

Figure 1: Treatment timeline with chest computed tomography (CT) and brain magnetic resonance images (MRI) on osimertinib.

Oncotarget

Case Report: Lazarus Effect in a Patient Treated With Osimertinib for NSCLC With Leptomeningeal Disease

January 24, 2024

this case supports a body of literature noting potentially dramatic clinical benefits of administering appropriate oncogene directed targeted therapy [...]”BUFFALO, NY- January 24, 2024 – A new case report was published... read more

Oncotarget

Obesity Paradox and Lung Cancer, Metformin-based Therapeutic Opportunity?

November 15, 2023

These findings suggest a strong sensitization by the addition of metformin in obese population, suggesting that biochemical and molecular differences influence the treatment response.”BUFFALO, NY- November 15, 2023 – A... read more